BRIEF published on 05/19/2026 at 07:05, 9 days 2 hours ago Innate Pharma at the Jefferies Global Healthcare Conference Immunotherapy Cancer Innate Pharma Therapeutic Antibodies Jefferies Conference
BRIEF published on 05/19/2026 at 07:05, 9 days 2 hours ago Innate Pharma à la Conférence Jefferies Global Healthcare Immunothérapie Cancer Innate Pharma Conférence Jefferies Anticorps Thérapeutiques
BRIEF published on 05/19/2026 at 07:05, 9 days 2 hours ago Innate Pharma participera à la conférence mondiale sur les soins de santé de Jefferies Biotechnologie Immunothérapie Traitement Du Cancer Innate Pharma Conférence Jefferies
BRIEF published on 05/19/2026 at 07:05, 9 days 2 hours ago Innate Pharma to Attend Jefferies Global Healthcare Conference Biotechnology Cancer Treatment Immunotherapy Innate Pharma Jefferies Conference
PRESS RELEASE published on 05/19/2026 at 07:00, 9 days 2 hours ago Informations privilégiées / Autres communiqués Innate Pharma participera à la conférence Jefferies Global Healthcare 2026 à New York. La société de biotechnologies développe des traitements d'immunothérapies contre le cancer Conference Cancer Innate Pharma Biotechnologies Immunothérapies
PRESS RELEASE published on 05/19/2026 at 07:00, 9 days 2 hours ago Inside Information / Other news releases Innate Pharma to participate in Jefferies Global Healthcare Conference on June 2-4, 2026 in New York, United States. Developing immunotherapies for cancer patients Biotechnology Innate Pharma Jefferies Global Healthcare Conference Immunothérapies Cancer Patients
BRIEF published on 04/17/2026 at 21:05, 1 month 10 days ago Innate Pharma presents interim results from the MATISSE trial at the AACR congress Lung Cancer Innate Pharma AACR 2026 IPH5201 Phase 2 MATISSE
BRIEF published on 04/17/2026 at 21:05, 1 month 10 days ago Innate Pharma Reveals Promising Interim Results in MATISSE Phase 2 Study Clinical Trials Lung Cancer Innate Pharma MATISSE Phase 2 IPH5201
BRIEF published on 04/17/2026 at 21:05, 1 month 10 days ago Innate Pharma dévoile des résultats intermédiaires prometteurs dans l'étude de phase 2 MATISSE Essais Cliniques Cancer Du Poumon Innate Pharma MATISSE Phase 2 IPH5201
BRIEF published on 04/17/2026 at 21:05, 1 month 10 days ago Innate Pharma présente des résultats intermédiaires de l'essai MATISSE au congrès AACR Cancer Du Poumon Innate Pharma AACR 2026 IPH5201 Phase 2 MATISSE
Published on 05/28/2026 at 08:00, 1 hour 6 minutes ago Touchstone Exploration Provides An Operational Update
Published on 05/28/2026 at 01:15, 7 hours 51 minutes ago JM Capital II Corp. Announces Departure of President, Chief Financial Officer and Chief Financial Officer Jay Freeman
Published on 05/28/2026 at 00:55, 8 hours 11 minutes ago First Helium Closes Oversubscribed $2.6 Million Placement
Published on 05/27/2026 at 23:42, 9 hours 24 minutes ago New Horizon Aircraft Ltd. Announces Closing of $25 Million Offering of Common Shares
Published on 05/28/2026 at 08:05, 1 hour 1 minute ago Hyundai Mobis Adopts Open Source for Mobility Software Development… Driving the Establishment of a Global Standard Platform!
Published on 05/28/2026 at 08:00, 1 hour 6 minutes ago KAP AG BEGINS THE NEW FINANCIAL YEAR IN LINE WITH EXPECTATIONS AND REAFFIRMS ITS GUIDANCE FORECAST FOR 2026
Published on 05/28/2026 at 08:00, 1 hour 6 minutes ago Adler Group S.A. announces results for 3M 2026 demonstrating progress with development disposals and solid performance
Published on 05/28/2026 at 07:30, 1 hour 36 minutes ago EVN AG: Business development in the first half of 2025/26
Published on 05/28/2026 at 08:45, 21 minutes ago Appointment of Mikael Frenkian as Chief Executive Officer of Baikowski
Published on 05/28/2026 at 08:45, 21 minutes ago Nomination de Mikael Frenkian en qualité de Directeur Général de Baikowski
Published on 05/28/2026 at 08:30, 36 minutes ago Cegedim Business Services renforce sa conformité et sa sécurité avec deux distinctions majeures
Published on 05/27/2026 at 23:00, 10 hours 6 minutes ago BIOPHYTIS MODIFIE SA LIGNE DE FINANCEMENT AVEC HEXAGON CAPITAL FUND POUR RENDRE RENOUVELABLE SA CAPACITE DE TIRAGE DE 2M€
Published on 05/27/2026 at 23:00, 10 hours 6 minutes ago BIOPHYTIS CHANGES ITS FINANCING AGREEMENT WITH HEXAGON CAPITAL FUND TO ENSURE ITS €2 MILLION FACILITY IS RENEWABLE
